retatrutide trials for weight loss: Study shows 30% body weight loss Looking forward to when #retatrutide's

Zepbound (tirzepatide) Approved - A once-weekly injectable medication approved by the FDA in November 2023 for chronic weight management

They provide an anti-inflammatory benefit, largely because they help reduce visceral (intra-abdominal) fat, which is itself, highly inflammatory tissue

Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial

Nephrotoxicity of herbal products in Europea review of an underestimated problem

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies

The hypothalamus acts like a master switchboard, integrating a variety of hunger and satiety signals/inputs